首页 > 最新文献

AsiaIntervention最新文献

英文 中文
Clinical expert consensus document on the use of percutaneous left ventricular assist devices during complex high-risk PCI in India using a standardised algorithm. 临床专家共识文件在复杂的高风险PCI中使用经皮左心室辅助装置在印度使用标准化算法。
Pub Date : 2022-10-01 DOI: 10.4244/AIJ-D-22-00021
Rajiv Tayal, Sanjog Kalra, Ashok Seth, Praveen Chandra, Sumit Sohal, Kirti Punamiya, Ravinder Rao, Vishal Rastogi, P L N Kapardhi, Sanjeev Sharma, Prathap Kumar, Jaspal Arneja, Rony Mathew, Dilip Kumar, N K Mahesh, Vijay Trehan

Over the past decade, percutaneous left ventricular assist devices (pLVAD), such as the Impella microaxial flow pump (Abiomed), have been increasingly used to provide haemodynamic support during complex and high-risk revascularisation procedures to reduce the risk of intraprocedural haemodynamic compromise and to facilitate complete and optimal revascularisation. A global consensus on patient selection for the use of pLVADs, however, is currently lacking. Access to these devices is different across the world, thus, individual health care environments need to create and refine patient selection paradigms to optimise the use of these devices. The Impella pLVAD has recently been introduced in India and is being used in several centres in the management of high-risk percutaneous coronary intervention (PCI) and cardiogenic shock. With this increasing utilisation, there is a need for a standardised evaluation protocol to guide Impella use that factors in the unique economic and infrastructural characteristics of India's health care system to ensure that the needs of patients are optimally managed. In this consensus document, we present an algorithm to guide Impella use in Indian patients: to establish a standardised patient selection and usage paradigm that will allow both optimal patient outcomes and ongoing data collection.

在过去的十年中,经皮左心室辅助装置(pLVAD),如Impella微轴流泵(Abiomed),已越来越多地用于在复杂和高风险的血运重建过程中提供血流动力学支持,以降低术中血流动力学损害的风险,并促进完整和最佳的血运重建。然而,目前在患者选择使用plvad方面缺乏全球共识。世界各地使用这些设备的情况各不相同,因此,各个医疗保健环境需要创建和完善患者选择范例,以优化这些设备的使用。Impella pLVAD最近在印度推出,并在几个中心用于管理高风险经皮冠状动脉介入治疗(PCI)和心源性休克。随着这种利用的增加,有必要制定一个标准化的评估方案来指导Impella使用印度医疗保健系统独特的经济和基础设施特征,以确保患者的需求得到最佳管理。在这份共识文件中,我们提出了一种算法来指导Impella在印度患者中的使用:建立一个标准化的患者选择和使用范例,以实现最佳的患者结果和持续的数据收集。
{"title":"Clinical expert consensus document on the use of percutaneous left ventricular assist devices during complex high-risk PCI in India using a standardised algorithm.","authors":"Rajiv Tayal,&nbsp;Sanjog Kalra,&nbsp;Ashok Seth,&nbsp;Praveen Chandra,&nbsp;Sumit Sohal,&nbsp;Kirti Punamiya,&nbsp;Ravinder Rao,&nbsp;Vishal Rastogi,&nbsp;P L N Kapardhi,&nbsp;Sanjeev Sharma,&nbsp;Prathap Kumar,&nbsp;Jaspal Arneja,&nbsp;Rony Mathew,&nbsp;Dilip Kumar,&nbsp;N K Mahesh,&nbsp;Vijay Trehan","doi":"10.4244/AIJ-D-22-00021","DOIUrl":"https://doi.org/10.4244/AIJ-D-22-00021","url":null,"abstract":"<p><p>Over the past decade, percutaneous left ventricular assist devices (pLVAD), such as the Impella microaxial flow pump (Abiomed), have been increasingly used to provide haemodynamic support during complex and high-risk revascularisation procedures to reduce the risk of intraprocedural haemodynamic compromise and to facilitate complete and optimal revascularisation. A global consensus on patient selection for the use of pLVADs, however, is currently lacking. Access to these devices is different across the world, thus, individual health care environments need to create and refine patient selection paradigms to optimise the use of these devices. The Impella pLVAD has recently been introduced in India and is being used in several centres in the management of high-risk percutaneous coronary intervention (PCI) and cardiogenic shock. With this increasing utilisation, there is a need for a standardised evaluation protocol to guide Impella use that factors in the unique economic and infrastructural characteristics of India's health care system to ensure that the needs of patients are optimally managed. In this consensus document, we present an algorithm to guide Impella use in Indian patients: to establish a standardised patient selection and usage paradigm that will allow both optimal patient outcomes and ongoing data collection.</p>","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706744/pdf/AIJ-D-22-00021_Tayal.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10373205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Choosing the appropriate catheter and wire in peripheral intervention. 选择合适的导管和导线进行外周介入治疗。
Pub Date : 2022-10-01 DOI: 10.4244/AIJ-D-22-00016
Sidhi Laksono, R Mohammad Reza Juniery Pasciolly, Haris Munirwan, Ahmad Pandu Pratama, Ananta Siddhi Prawara

Endovascular treatment is becoming more common in managing patients with peripheral arterial disease. A carefully planned procedure is crucial for the outcome of the procedure. Several steps are necessary when performing endovascular procedures, including preplanning with vascular imaging using computed tomography angiography (CTA) or magnetic resonance angiography (MRA), choosing the right access and technique, and using the right devices (guidewires, sheaths, catheters). The length, diameter, stiffness, coating, and tip shape of the guidewire should be adjusted according to the initial information and preparation. A sheath is not always necessary but can be beneficial when several catheter changes are planned. There are three types of angiographic catheter (flush, exchange, and selective), each of which should be considered and used wisely according to its function. The guidewire, sheath, and catheter choices will follow from the initial information gathered, the access and technique chosen, and the availability of the devices.

血管内治疗在治疗外周动脉疾病患者中越来越普遍。精心策划的手术对手术的结果至关重要。在进行血管内手术时,有几个步骤是必要的,包括使用计算机断层血管造影(CTA)或磁共振血管造影(MRA)预先规划血管成像,选择正确的通道和技术,并使用正确的设备(导丝、鞘、导管)。导丝的长度、直径、刚度、涂层和尖端形状应根据初始信息和准备进行调整。护套并不总是必需的,但在计划多次更换导管时是有益的。血管造影导管有三种类型(冲洗、置换和选择性),每一种都应考虑并根据其功能明智地使用。导丝、护套和导管的选择将根据最初收集的信息、选择的途径和技术以及设备的可用性进行。
{"title":"Choosing the appropriate catheter and wire in peripheral intervention.","authors":"Sidhi Laksono,&nbsp;R Mohammad Reza Juniery Pasciolly,&nbsp;Haris Munirwan,&nbsp;Ahmad Pandu Pratama,&nbsp;Ananta Siddhi Prawara","doi":"10.4244/AIJ-D-22-00016","DOIUrl":"https://doi.org/10.4244/AIJ-D-22-00016","url":null,"abstract":"<p><p>Endovascular treatment is becoming more common in managing patients with peripheral arterial disease. A carefully planned procedure is crucial for the outcome of the procedure. Several steps are necessary when performing endovascular procedures, including preplanning with vascular imaging using computed tomography angiography (CTA) or magnetic resonance angiography (MRA), choosing the right access and technique, and using the right devices (guidewires, sheaths, catheters). The length, diameter, stiffness, coating, and tip shape of the guidewire should be adjusted according to the initial information and preparation. A sheath is not always necessary but can be beneficial when several catheter changes are planned. There are three types of angiographic catheter (flush, exchange, and selective), each of which should be considered and used wisely according to its function. The guidewire, sheath, and catheter choices will follow from the initial information gathered, the access and technique chosen, and the availability of the devices.</p>","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706725/pdf/AIJ-D-22-00016_Laksono.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10373206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous coronary intervention in patients aged 80 years old and above: a systematic review and meta-analysis. 80岁及以上患者经皮冠状动脉介入治疗:一项系统回顾和荟萃分析。
Pub Date : 2022-10-01 DOI: 10.4244/AIJ-D-21-00040
Norman H Lin, Jamie S-Y Ho, Andie Hartanto Djohan, Vanda Wen-Teng Ho, Yao Neng Teo, Yao Hao Teo, Nicholas L Syn, Yin Nwe Aye, Rodney Y H Soh, Tiong-Cheng Yeo, Hui-Wen Sim, Huay-Cheem Tan, Mark Y Chan, Ching-Hui Sia

Background: Ischaemic heart disease remains the main cause of death in the world. With increasing age, frailty and comorbidities, senior patients aged 80 years old and above who undergo percutaneous coronary intervention (PCI) are at higher risk of mortality and other complications.

Aims: We aimed to examine the overall outcomes for this group of patients.

Methods: Four databases (PUBMED, EMBASE, SCOPUS and CENTRAL) were searched. Studies with patients aged 80 years old and above who underwent PCI for all indications were included. Pooled outcomes of all-cause death, cardiac death, in-hospital death, subsequent stroke/transient ischaemic attack (TIA), subsequent myocardial infarction (MI), subsequent congestive cardiac failure (CCF), and overall major adverse cardiac events (MACE) were obtained for meta-analysis.

Results: From 2,566,004 patients, the pooled cumulative incidence of death was 19.22%, cardiac death was 7.78%, in-hospital death was 7.16%, subsequent stroke/TIA was 1.54%, subsequent MI was 3.58%, subsequent CCF was 4.74%, and MACE was 17.51%. The mortality rate of all patients was high when followed up for 3 years (33.27%). ST-elevation myocardial infarction patients had more outcomes of in-hospital death (14.24% vs 4.89%), stroke/TIA (1.93% vs 0.12%), MI (3.68 vs 1.55%) and 1-year mortality (26.16% vs 13.62%), when compared to non-ST-elevation myocardial infarction patients.

Conclusions: There was a high mortality rate at 1 year and 3 years post-PCI in the overall population of senior patients aged 80 years old and above, regardless of indication. This necessitates further studies to explore the implications of these observations.

背景:缺血性心脏病仍然是世界上死亡的主要原因。80岁及以上高龄患者行经皮冠状动脉介入治疗(PCI),随着年龄的增长、身体虚弱和合并症的增加,其死亡和其他并发症的风险更高。目的:我们的目的是检查这组患者的总体结果。方法:检索PUBMED、EMBASE、SCOPUS和CENTRAL 4个数据库。研究纳入了80岁及以上因所有适应症接受PCI治疗的患者。全因死亡、心源性死亡、院内死亡、随后的中风/短暂性缺血发作(TIA)、随后的心肌梗死(MI)、随后的充血性心力衰竭(CCF)和总体主要心脏不良事件(MACE)的汇总结果进行meta分析。结果:2,566,004例患者中,合并累积死亡发生率为19.22%,心源性死亡为7.78%,院内死亡为7.16%,随后卒中/TIA发生率为1.54%,随后MI发生率为3.58%,随后CCF发生率为4.74%,MACE发生率为17.51%。随访3年死亡率均较高(33.27%)。与非st段抬高型心肌梗死患者相比,st段抬高型心肌梗死患者有更多的院内死亡(14.24%对4.89%)、卒中/TIA(1.93%对0.12%)、心肌梗死(3.68对1.55%)和1年死亡率(26.16%对13.62%)。结论:80岁及以上老年患者pci术后1年和3年的死亡率均较高,与适应证无关。这需要进一步的研究来探索这些观察结果的含义。
{"title":"Percutaneous coronary intervention in patients aged 80 years old and above: a systematic review and meta-analysis.","authors":"Norman H Lin,&nbsp;Jamie S-Y Ho,&nbsp;Andie Hartanto Djohan,&nbsp;Vanda Wen-Teng Ho,&nbsp;Yao Neng Teo,&nbsp;Yao Hao Teo,&nbsp;Nicholas L Syn,&nbsp;Yin Nwe Aye,&nbsp;Rodney Y H Soh,&nbsp;Tiong-Cheng Yeo,&nbsp;Hui-Wen Sim,&nbsp;Huay-Cheem Tan,&nbsp;Mark Y Chan,&nbsp;Ching-Hui Sia","doi":"10.4244/AIJ-D-21-00040","DOIUrl":"https://doi.org/10.4244/AIJ-D-21-00040","url":null,"abstract":"<p><strong>Background: </strong>Ischaemic heart disease remains the main cause of death in the world. With increasing age, frailty and comorbidities, senior patients aged 80 years old and above who undergo percutaneous coronary intervention (PCI) are at higher risk of mortality and other complications.</p><p><strong>Aims: </strong>We aimed to examine the overall outcomes for this group of patients.</p><p><strong>Methods: </strong>Four databases (PUBMED, EMBASE, SCOPUS and CENTRAL) were searched. Studies with patients aged 80 years old and above who underwent PCI for all indications were included. Pooled outcomes of all-cause death, cardiac death, in-hospital death, subsequent stroke/transient ischaemic attack (TIA), subsequent myocardial infarction (MI), subsequent congestive cardiac failure (CCF), and overall major adverse cardiac events (MACE) were obtained for meta-analysis.</p><p><strong>Results: </strong>From 2,566,004 patients, the pooled cumulative incidence of death was 19.22%, cardiac death was 7.78%, in-hospital death was 7.16%, subsequent stroke/TIA was 1.54%, subsequent MI was 3.58%, subsequent CCF was 4.74%, and MACE was 17.51%. The mortality rate of all patients was high when followed up for 3 years (33.27%). ST-elevation myocardial infarction patients had more outcomes of in-hospital death (14.24% vs 4.89%), stroke/TIA (1.93% vs 0.12%), MI (3.68 vs 1.55%) and 1-year mortality (26.16% vs 13.62%), when compared to non-ST-elevation myocardial infarction patients.</p><p><strong>Conclusions: </strong>There was a high mortality rate at 1 year and 3 years post-PCI in the overall population of senior patients aged 80 years old and above, regardless of indication. This necessitates further studies to explore the implications of these observations.</p>","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706774/pdf/AIJ-D-21-00040_Lin.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10433814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aggressive lipid lowering post-PCI; excimer laser for treating in-stent restenosis of undilatable stents; intravascular lithotripsy for calcified lesion PCI; robotic angioplasty for complex lesions; pulmonary artery denervation to treat PAH; and more…. pci术后积极降脂;准分子激光治疗支架内不可扩张再狭窄钙化病变的血管内碎石;复杂病变的机器人血管成形术;肺动脉去神经治疗PAH;和更多的……
Pub Date : 2022-03-01 DOI: 10.4244/aij-e-22-00003
U. Kaul
{"title":"Aggressive lipid lowering post-PCI; excimer laser for treating in-stent restenosis of undilatable stents; intravascular lithotripsy for calcified lesion PCI; robotic angioplasty for complex lesions; pulmonary artery denervation to treat PAH; and more….","authors":"U. Kaul","doi":"10.4244/aij-e-22-00003","DOIUrl":"https://doi.org/10.4244/aij-e-22-00003","url":null,"abstract":"","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85206695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements in robotic PCI technology: time to tackle the complex lesions!: Technological advancements in robotic PCI. 机器人PCI技术的进步:是时候解决复杂病变了!:机器人PCI的技术进步。
Pub Date : 2022-03-01 DOI: 10.4244/aij-d-21-00034
A. Khokhar, Aleksander Zelias, A. Złahoda-Huzior, Krishno Chandra, R. Ruggiero, M. Toselli, Francesco Giannini, D. Dudek
{"title":"Advancements in robotic PCI technology: time to tackle the complex lesions!: Technological advancements in robotic PCI.","authors":"A. Khokhar, Aleksander Zelias, A. Złahoda-Huzior, Krishno Chandra, R. Ruggiero, M. Toselli, Francesco Giannini, D. Dudek","doi":"10.4244/aij-d-21-00034","DOIUrl":"https://doi.org/10.4244/aij-d-21-00034","url":null,"abstract":"","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88428691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Percutaneous atrial septal defect closure in a case of Poland syndrome with dextrocardia: ASD closure in Poland syndrome with dextrocardia. 经皮房间隔缺损关闭波兰综合征右心:ASD关闭波兰综合征右心。
Pub Date : 2022-03-01 DOI: 10.4244/aij-d-21-00038
A. Bafna, Varun Deokate
{"title":"Percutaneous atrial septal defect closure in a case of Poland syndrome with dextrocardia: ASD closure in Poland syndrome with dextrocardia.","authors":"A. Bafna, Varun Deokate","doi":"10.4244/aij-d-21-00038","DOIUrl":"https://doi.org/10.4244/aij-d-21-00038","url":null,"abstract":"","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75392581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The modified interventional method of antegrade common femoral artery access closure using the Angio-Seal device: modified Angio-Seal haemostasis technique: Modified Angio-Seal haemostasis technique. 改良的血管-密封装置顺行股总动脉通路封闭介入方法:改良血管-密封止血技术:改良血管-密封止血技术。
Pub Date : 2022-03-01 DOI: 10.4244/aij-d-21-00032
Yusuke Watanabe, Koji Hozawa, Sunao Nakamura
AimsAntegrade femoral puncture is frequently performed in endovascular therapy, with haemostasis achieved through manual compression. The aim of this paper is to report the novel method of achieving haemostasis using the Angio-Seal device for antegrade punctures of the femoral artery.Methods and resultsBetween September 2017 and March 2018, a total of 50 consecutive patients who underwent endovascular therapies (EVT) through the common femoral artery with an antegrade puncture using a 6 Fr introducer sheath were retrospectively analysed. After EVT, all patients received a 6 Fr Angio-Seal STS Plus Vascular Closure Device. All procedures were performed using the following new technique. First, we inserted the Angio-Seal guidewire from the inserted EVT sheath into the artery. Second, we removed the EVT sheath and inserted the Angio-Seal sheath and then removed the dilator and Angio-Seal guidewire. Under angiography using an 18 G needle sheath, we pulled back the Angio-Seal sheath as near to the insertion site of the vessel as possible. Finally, a collagen sponge and plug were inserted as per the standard technique. In all patients, the Angio-Seal was successfully deployed, and haemostasis was achieved within several minutes. No major complications occurred.ConclusionsWe demonstrated the feasibility and efficacy of achieving haemostasis using the Angio-Seal device in an antegrade femoral puncture using the novel method.
AimsAntegrade股动脉穿刺常用于血管内治疗,通过手压止血。本文的目的是报告使用血管密封装置实现股动脉顺行穿刺止血的新方法。方法和结果回顾性分析2017年9月至2018年3月期间,共50例连续通过股总动脉行血管内治疗(EVT)并使用6fr引入器鞘顺行穿刺的患者。EVT后,所有患者接受6 Fr血管密封STS +血管关闭装置。所有手术均采用以下新技术进行。首先,我们将血管密封导丝从插入的EVT鞘插入动脉。其次,我们取出EVT鞘并插入Angio-Seal鞘,然后取出扩张器和Angio-Seal导丝。在使用18g针鞘的血管造影下,我们将血管密封鞘拉回尽可能靠近血管的插入部位。最后,按照标准技术插入胶原蛋白海绵和胶塞。在所有患者中,Angio-Seal都成功部署,并在几分钟内实现止血。无重大并发症发生。结论我们证明了在顺行股动脉穿刺中使用血管密封装置止血的可行性和有效性。
{"title":"The modified interventional method of antegrade common femoral artery access closure using the Angio-Seal device: modified Angio-Seal haemostasis technique: Modified Angio-Seal haemostasis technique.","authors":"Yusuke Watanabe, Koji Hozawa, Sunao Nakamura","doi":"10.4244/aij-d-21-00032","DOIUrl":"https://doi.org/10.4244/aij-d-21-00032","url":null,"abstract":"Aims\u0000Antegrade femoral puncture is frequently performed in endovascular therapy, with haemostasis achieved through manual compression. The aim of this paper is to report the novel method of achieving haemostasis using the Angio-Seal device for antegrade punctures of the femoral artery.\u0000\u0000\u0000Methods and results\u0000Between September 2017 and March 2018, a total of 50 consecutive patients who underwent endovascular therapies (EVT) through the common femoral artery with an antegrade puncture using a 6 Fr introducer sheath were retrospectively analysed. After EVT, all patients received a 6 Fr Angio-Seal STS Plus Vascular Closure Device. All procedures were performed using the following new technique. First, we inserted the Angio-Seal guidewire from the inserted EVT sheath into the artery. Second, we removed the EVT sheath and inserted the Angio-Seal sheath and then removed the dilator and Angio-Seal guidewire. Under angiography using an 18 G needle sheath, we pulled back the Angio-Seal sheath as near to the insertion site of the vessel as possible. Finally, a collagen sponge and plug were inserted as per the standard technique. In all patients, the Angio-Seal was successfully deployed, and haemostasis was achieved within several minutes. No major complications occurred.\u0000\u0000\u0000Conclusions\u0000We demonstrated the feasibility and efficacy of achieving haemostasis using the Angio-Seal device in an antegrade femoral puncture using the novel method.","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74746622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aggressive lipid-lowering therapy after percutaneous coronary intervention - for whom and how?: Aggressive lipid-lowering therapy after PCI. 经皮冠状动脉介入治疗后积极的降脂治疗-对谁以及如何治疗?PCI术后积极的降脂治疗。
Pub Date : 2022-03-01 DOI: 10.4244/aij-d-22-00005
Zhen-Vin Lee, H. Lam
Percutaneous coronary intervention (PCI) has been established as a definitive method to treat obstructive coronary artery disease. The procedure on its own, however, is insufficient to ensure optimal long-term patient outcomes as it is also necessary to achieve good control of relevant risk factors. The process of atherosclerosis as a result of dyslipidaemia is a risk continuum and secondary preventive measures for patients who have undergone PCI are of paramount importance to mitigate the risk of procedural failure and further cardiovascular events. This review aims to provide an overview of the landscape of lipid-lowering therapy for the purpose of secondary prevention by summarising recommendations derived from contemporary guidelines and highlighting the rationale and evidence behind the three main lipid-lowering therapies, namely statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. It also provides insights into real-world challenges and issues surrounding secondary prevention of dyslipidaemia such as suboptimal lipid goal attainment and nonadherence, and assesses the possible methods to overcome them.
经皮冠状动脉介入治疗(PCI)已被确立为治疗阻塞性冠状动脉疾病的确定方法。然而,手术本身并不足以确保最佳的长期患者预后,因为对相关危险因素的良好控制也是必要的。血脂异常导致的动脉粥样硬化过程是一个风险连续体,对于接受PCI的患者,二级预防措施对于降低手术失败和进一步心血管事件的风险至关重要。本综述旨在通过总结来自当代指南的建议,并强调三种主要降脂疗法的基本原理和证据,即他汀类药物、依折麦布和蛋白转化酶枯草杆菌素/ keexin 9型(PCSK9)抑制剂,概述以二级预防为目的的降脂疗法的概况。它还提供了关于血脂异常二级预防的现实世界挑战和问题的见解,如脂质目标达到不理想和不依从性,并评估了克服这些问题的可能方法。
{"title":"Aggressive lipid-lowering therapy after percutaneous coronary intervention - for whom and how?: Aggressive lipid-lowering therapy after PCI.","authors":"Zhen-Vin Lee, H. Lam","doi":"10.4244/aij-d-22-00005","DOIUrl":"https://doi.org/10.4244/aij-d-22-00005","url":null,"abstract":"Percutaneous coronary intervention (PCI) has been established as a definitive method to treat obstructive coronary artery disease. The procedure on its own, however, is insufficient to ensure optimal long-term patient outcomes as it is also necessary to achieve good control of relevant risk factors. The process of atherosclerosis as a result of dyslipidaemia is a risk continuum and secondary preventive measures for patients who have undergone PCI are of paramount importance to mitigate the risk of procedural failure and further cardiovascular events. This review aims to provide an overview of the landscape of lipid-lowering therapy for the purpose of secondary prevention by summarising recommendations derived from contemporary guidelines and highlighting the rationale and evidence behind the three main lipid-lowering therapies, namely statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. It also provides insights into real-world challenges and issues surrounding secondary prevention of dyslipidaemia such as suboptimal lipid goal attainment and nonadherence, and assesses the possible methods to overcome them.","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78778658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How should we treat "undilatable" coronary stents?: Treating "undilatable" coronary stents. 如何处理 "无法膨胀 "的冠状动脉支架?治疗 "无法膨胀 "的冠状动脉支架。
Pub Date : 2022-03-01 Epub Date: 2022-03-15 DOI: 10.4244/AIJ-E-22-00002
Fernando Alfonso, J J Coughlan, Adnan Kastrati
{"title":"How should we treat \"undilatable\" coronary stents?: Treating \"undilatable\" coronary stents.","authors":"Fernando Alfonso, J J Coughlan, Adnan Kastrati","doi":"10.4244/AIJ-E-22-00002","DOIUrl":"10.4244/AIJ-E-22-00002","url":null,"abstract":"","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89105260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Initial experience of a single referral centre using excimer laser coronary atherectomy-assisted expansion in undilatable stents: Excimer laser in undilatable stents. 单个转诊中心使用准分子激光冠状动脉切除术辅助扩张不可扩张支架的初步经验:准分子激光在不可扩张支架中的应用。
Pub Date : 2022-03-01 DOI: 10.4244/aij-d-21-00024
D. Adikari, R. Giles, N. Jepson, M. Pitney
AimsUndilatable stents with severe peri-stent calcification are an important cause of target lesion failure and therapeutic options are limited. We report our initial experience with the safety and efficacy of excimer laser coronary atherectomy (ELCA)-assisted expansion of undilatable stents.Methods and resultsELCA was performed with saline, blood and contrast-enhanced trains. All lesions were post-dilated at high pressures and treated with a drug-eluting balloon. Thirty-one lesions with undilatable stents were included at a single centre with experienced operators from March 2016 to February 2021. The mean number of prior procedures for in-stent restenosis was three and 14 lesions had multiple layers of stent. Procedural success (>50% increase in minimal stent diameter [MSD]) and adequate stent expansion (MSD >70% of reference vessel diameter) was achieved in all lesions. At six-month follow-up (N=26 lesions), there were six periprocedural myocardial infarctions due to slow flow, two cardiac deaths and one target lesion revascularisation. There were no perforations.ConclusionsOur niche experience at a centre with experienced operators demonstrated that ELCA led to larger final lumen and stent dimensions in highly selected patients with undilatable stents and recurrent restenosis at the cost of relatively frequent slow flow.
不可扩张支架伴支架周围严重钙化是靶病变失败的重要原因,治疗选择有限。我们报告了准分子激光冠状动脉粥样硬化切除术(ELCA)辅助扩张不可扩张支架的安全性和有效性的初步经验。方法与结果selca采用生理盐水、血液和增强显影。所有病变均在高压下扩张,并用药物洗脱球囊治疗。2016年3月至2021年2月,在经验丰富的操作人员的指导下,在一个中心研究了31个带有不可扩张支架的病变。支架内再狭窄的平均手术次数为3次,14个病变有多层支架。手术成功(最小支架直径[MSD]增加>50%)和适当的支架扩张(MSD >参考血管直径的70%)在所有病变中都获得了成功。在6个月的随访中(N=26个病变),有6例术中心肌梗死是由于血流缓慢,2例心源性死亡和1例靶病变血运重建。没有穿孔。结论:我们在一个经验丰富的操作人员中心的经验表明,ELCA在高度选择的支架不可扩张和复发性再狭窄的患者中,以相对频繁的慢血流为代价,导致更大的最终管腔和支架尺寸。
{"title":"Initial experience of a single referral centre using excimer laser coronary atherectomy-assisted expansion in undilatable stents: Excimer laser in undilatable stents.","authors":"D. Adikari, R. Giles, N. Jepson, M. Pitney","doi":"10.4244/aij-d-21-00024","DOIUrl":"https://doi.org/10.4244/aij-d-21-00024","url":null,"abstract":"Aims\u0000Undilatable stents with severe peri-stent calcification are an important cause of target lesion failure and therapeutic options are limited. We report our initial experience with the safety and efficacy of excimer laser coronary atherectomy (ELCA)-assisted expansion of undilatable stents.\u0000\u0000\u0000Methods and results\u0000ELCA was performed with saline, blood and contrast-enhanced trains. All lesions were post-dilated at high pressures and treated with a drug-eluting balloon. Thirty-one lesions with undilatable stents were included at a single centre with experienced operators from March 2016 to February 2021. The mean number of prior procedures for in-stent restenosis was three and 14 lesions had multiple layers of stent. Procedural success (>50% increase in minimal stent diameter [MSD]) and adequate stent expansion (MSD >70% of reference vessel diameter) was achieved in all lesions. At six-month follow-up (N=26 lesions), there were six periprocedural myocardial infarctions due to slow flow, two cardiac deaths and one target lesion revascularisation. There were no perforations.\u0000\u0000\u0000Conclusions\u0000Our niche experience at a centre with experienced operators demonstrated that ELCA led to larger final lumen and stent dimensions in highly selected patients with undilatable stents and recurrent restenosis at the cost of relatively frequent slow flow.","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85481676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
AsiaIntervention
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1